Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer.
Currently head and neck squamous cell-carcinomas are staged clinically, though this is not ideal. We did a multivariate prospective study of 234 patients with head and neck squamous-cell carcinoma and showed that high serum concentrations of sIL-2Ralpha at diagnosis were highly correlated with a shorter survival (p<0.0001). In addition, patients who had low serum sIL-2Ralpha concentrations at diagnosis were less likely to develop distant metastasis during the 36 months follow up compared with the group with high serum sIL-2Ralpha concentrations (p<0.001). These findings suggest that serum sIL-2Ralpha could be considered as an independent serum biomarker in head and neck cancer patients.
Tartour
E
E
Mosseri
V
V
Jouffroy
T
T
Deneux
L
L
Jaulerry
C
C
Brunin
F
F
Fridman
W H
WH
Rodriguez
J
J
D014408:Biomarkers, Tumor; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000401:mortality; D006258:Head and Neck Neoplasms / Q000097:blood* / Q000401:mortality; D006801:Humans; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000097:blood*; D015996:Survival Rate
D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2